CorMedix Inc.CRMDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+79.4%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

5Y CAGR
+79.4%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
18.6x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025390.40%
2024-70.03%
202323.18%
2022-18.68%
2021-1.83%
202021.03%
2019-41.28%
2018-23.13%
201755.61%
2016150.49%